Inhibition of TGFβ1 causes a robust antitumor immune response and tumor regression (Holmgaard et al., 2018; Knudson et al., 2018; Mariathasan et al., 2018; Ravi et al., 2018; Lind et al., 2020). Here, TGFB1 is linked to neoplasm.